ABL1 and leukemia: Most importantly, when we checked the literature findings for the involvement of miR-125b in leukemia, miR-125b overexpression was reported to accelerate the oncogenic nature of the BCR-ABL oncoprotein as a trigger to induce primary lymphoid or myeloid leukemia and was therefore to be considered a therapy target (Bousquet et al. 2010).